Search

Your search keyword '"Serratosa, José M."' showing total 205 results
Start Over Author "Serratosa, José M."
205 results on '"Serratosa, José M."'

1. La investigación en Ciencia de Materiales en España. Evolución en los últimos 30 años

Author

Serratosa, José M.

Subjects
Material, Science, Technology, Scientific, Research, Programmes, Publshed, Articles, Citations, Impacts, Evaluation, Analysis, R&D, Industry, Ciencia, Tecnología, Materiales, Financiación, investigación, Publicaciones, impacto internacional, Evaluación, Investigación, empresa, Clay industries. Ceramics. Glass, TP785-869
Abstract

The great development experienced by material research in Spain during the last 30 years has been, in great part, a consequence of the initiative of the National Research Council of Spain (CSIC) of including Material Science as a priority area in its Scientific Programme in the years 1980. Four new institutes for research in advanced materials were created in 1985-1986 in Barcelona, Madrid, Sevilla and Zaragoza , the last two in cooperation with the respective universities. A Scientific Advisory Committee, whose members were scientists of great prestige at the international level, was nominated by the CSIC in order to guarantee a high standard in the research activities of the new centres. Sources for funding material research projects existed at three levels: a) the Framework Programme of the European Unión; b) the National Programme for Scientific Research and Tchnological development of the Spanish Governement and c) the Institutional Research Programme of the CSIC. An important increase of the research activity has taken place during the last 30 years, as indicated by the number of papers published in international journals, Finally, an análiysis of the actual situation of research activities in material research concerning the public sector (universities and research organisms) and the industrial sector, is presented.El desarrollo de la investigación en Ciencia de Materiales que ha tenido lugar en España durante los últimos 30 años, se ha debido, en gran parte, a la iniciativa del CSIC de incluir la Ciencia de Materiales como área prioritario en su programación científica en los años 1980. El CSIC creó, en 1985-1986, cuatro institutos de Ciencia de Materiales en Barcelona, Madrid, Sevilla y Zaragoza, los dos últimos como centros mixtos Universidad-CSIC. Para el desarrollo de la labor científica de estos centros, el CSIC creó un Comité Científico Asesor formado por científicos de gran prestigio internacional en esta área. La financiación de proyectos de investigación en Ciencia de Materiales quedó establecida a tres niveles: a) El Programa Marco de la Unión Europea, b) El Programa Nacional de Investigación Científica y Desarrollo Tecnológico, y c) El Programa Sectorial del CSIC. En los últimos 30 años se ha producido un importante aumento en la actividad científica del área, como lo prueba el numero de artículos publicados en revistas internacionales. Finalmente se hace un análisis y evaluación de la situación actual de esta área en el sector público (universidades y organismos de investigación) y en el sector industrial.

Published
2010

3. Cartas Homenaje a Salvador de Aza

Author

María Mato, José, Martín-Lomas, Manuel, Brook, Richard, Fantozzi, Gilbert, Dominguez, Carlos, Navarras, Magnesitas, Cambier, Francis, Torrecillas, Ramón, Espinosa de los Monteros, Juan, Serratosa, José M., Aglietti, Esteban, Scian, Alberto, Topolevsky, Raul, Bellandi, Norberto, and Iglesias, Juan Eugenio

Subjects
Clay industries. Ceramics. Glass, TP785-869
Published
2011

10. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug‐resistant focal seizures.

Author

Carreño, Mar, Gil‐Nagel, Antonio, Serratosa, José M., Toledo, Manuel, Rodriguez‐Uranga, Juan Jesus, and Villanueva, Vicente

Subjects
PHENOBARBITAL, SEIZURES (Medicine), SODIUM channel blockers, ADULTS, DELPHI method, PEOPLE with epilepsy
Abstract

Objective: Cenobamate is an antiseizure medication (ASM) associated with high rates of seizure freedom and acceptable tolerability in patients with focal seizures. To achieve the optimal cenobamate dose for maximal potential effectiveness while avoiding or minimizing drug‐related adverse events (AEs), the administration of cenobamate with other ASMs must be managed through concomitant ASM load reduction. A panel of Spanish epilepsy experts aimed to provide a Spanish consensus on how to adjust the dose of concomitant ASMs in patients with drug‐resistant epilepsy (DRE) in order to improve the effectiveness and tolerability of adjunctive cenobamate. Methods: A three‐stage modified Delphi consensus process was undertaken, including six Spanish epileptologists with extensive experience using cenobamate. Based on current literature and their own expert opinion, the expert panel reached a consensus on when and how to adjust the dosage of concomitant ASMs during cenobamate titration. Results: The expert panel agreed that tailored titration and close follow‐up are required to achieve the best efficacy and tolerability when initiating cenobamate in patients receiving concomitant ASMs. When concomitant clobazam, phenytoin, phenobarbital, and sodium channel blockers are taken at high dosages, or when the patient is receiving two or more sodium channel blockers, dosages should be proactively lowered during the cenobamate titration period. Other concomitant ASMs should be reduced only if the patient reports a moderate/severe AE at any stage of the titration period. Significance: Cenobamate is an effective ASM with a dose‐dependent effect. To maximize effectiveness while maintaining the best tolerability profile, co‐medication management is needed. The recommendations included herein provide practical guidance for proactive and reactive management of co‐medication in cenobamate‐treated patients with DRE and a high drug load. Plain Language Summary: Patients with epilepsy may continue to have seizures even after treatment with several different antiseizure medications (ASMs). Cenobamate is an ASM that can reduce seizures in these patients. In this study, six Spanish experts in epilepsy discussed the best way to use cenobamate in drug‐resistant epilepsy. They provide practical guidance on when and how the dose of other ASMs might be adjusted to reduce side effects and optimize the use of cenobamate. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Rare coding variants in genes encoding GABAA receptors in genetic generalised epilepsies: an exome-based case-control study

Author

May, Patrick, Girard, Simon, Harrer, Merle, Bobbili, Dheeraj R, Schubert, Julian, Wolking, Stefan, Becker, Felicitas, Lachance-Touchette, Pamela, Meloche, Caroline, Gravel, Micheline, Niturad, Cristina E, Knaus, Julia, De Kovel, Carolien, Toliat, Mohamad, Polvi, Anne, Iacomino, Michele, Guerrero-López, Rosa, Baulac, Stéphanie, Marini, Carla, Thiele, Holger, Altmüller, Janine, Jabbari, Kamel, Ruppert, Ann-Kathrin, Jurkowski, Wiktor, Lal, Dennis, Rusconi, Raffaella, Cestèle, Sandrine, Terragni, Benedetta, Coombs, Ian D, Reid, Christopher A, Striano, Pasquale, Caglayan, Hande, Siren, Auli, Everett, Kate, Møller, Rikke S, Hjalgrim, Helle, Muhle, Hiltrud, Helbig, Ingo, Kunz, Wolfram S, Weber, Yvonne G, Weckhuysen, Sarah, De Jonghe, Peter, Sisodiya, Sanjay M, Nabbout, Rima, Franceschetti, Silvana, Coppola, Antonietta, Vari, Maria S, Kasteleijn-Nolst Trenité, Dorothée, Baykan, Betul, Ozbek, Ugur, Bebek, Nerses, Klein, Karl M, Rosenow, Felix, Nguyen, Dang K, Dubeau, François, Carmant, Lionel, Lortie, Anne, Desbiens, Richard, Clément, Jean-François, Cieuta-Walti, Cécile, Sills, Graeme J, Auce, Pauls, Francis, Ben, Johnson, Michael R, Marson, Anthony G, Berghuis, Bianca, Sander, Josemir W, Avbersek, Andreja, McCormack, Mark, Cavalleri, Gianpiero L, Delanty, Norman, Depondt, Chantal, Krenn, Martin, Zimprich, Fritz, Peter, Sarah, Nikanorova, Marina, Kraaij, Robert, van Rooij, Jeroen, Balling, Rudi, Arfan Ikram, M, Uitterlinden, André G, Avanzini, Giuliano, Schorge, Stephanie, Petrou, Steven, Mantegazza, Massimo, Sander, Thomas, LeGuern, Eric, Serratosa, Jose M, Koeleman, Bobby P C, Palotie, Aarno, Lehesjoki, Anna-Elina, Nothnagel, Michael, Nürnberg, Peter, Maljevic, Snezana, Zara, Federico, Cossette, Patrick, Krause, Roland, Lerche, Holger, Ferlazzo, Edoardo, di Bonaventura, Carlo, La Neve, Angela, Tinuper, Paolo, Bisulli, Francesca, Vignoli, Aglaia, Capovilla, Giuseppe, Crichiutti, Giovanni, Gambardella, Antonio, Belcastro, Vincenzo, Bianchi, Amedeo, Yalçın, Destina, Dizdarer, Gulsen, Arslan, Kezban, Yapıcı, Zuhal, Kuşcu, Demet, Leu, Costin, Heggeli, Kristin, Willis, Joseph, Langley, Sarah R, Jorgensen, Andrea, Srivastava, Prashant, Rau, Sarah, Hengsbach, Christian, Sonsma, Anja C.M., Jonghe, Peter De, and Ikram, M Arfan

Published
2018
Full Text
View/download PDF

15. Antiepileptogenesis after stroke—trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate

Author

Koepp, Matthias J., primary, Trinka, Eugen, additional, Mah, Yee‐Haur, additional, Bentes, Carla, additional, Knake, Susanne, additional, Gigli, Gian Luigi, additional, Serratosa, José M., additional, Zelano, Johan, additional, Magalhães, Luís M., additional, Pereira, Ana, additional, Moreira, Joana, additional, and Soares‐da‐Silva, Patrício, additional

Published
2023
Full Text
View/download PDF

22. Variant Intestinal-Cell Kinase in Juvenile Myoclonic Epilepsy

Author

Bailey, Julia N., de Nijs, Laurence, Bai, Dongsheng, Suzuki, Toshimitsu, Miyamoto, Hiroyuki, Tanaka, Miyabi, Patterson, Christopher, Lin, Yu-Chen, Medina, Marco T., Alonso, María E., Serratosa, José M., Durón, Reyna M., Nguyen, Viet H., Wight, Jenny E., Martínez-Juárez, Iris E., Ochoa, Adriana, Jara-Prado, Aurelio, Guilhoto, Laura, Molina, Yolly, Yacubian, Elsa M., López-Ruiz, Minerva, Inoue, Yushi, Kaneko, Sunao, Hirose, Shinichi, Osawa, Makiko, Oguni, Hirokazu, Fujimoto, Shinji, Grisar, Thierry M., Stern, John M., Yamakawa, Kazuhiro, Lakaye, Bernard, and Delgado-Escueta, Antonio V.

Published
2018
Full Text
View/download PDF

23. Familial adult myoclonus epilepsy: Clinical findings, disease course, and comorbidities.

Author

Giraldez, Beatriz G., Serratosa, José M., Striano, Salvatore, Ikeda, Akio, Striano, Pasquale, and Coppola, Antonietta

Subjects
*DISEASE progression, *EPILEPSY, *MYOCLONUS, *GENETIC techniques, *COMORBIDITY, *ADULTS, *LIFE expectancy
Abstract

Familial adult myoclonus epilepsy (FAME) is an autosomal dominant condition characterized by the association of myoclonic tremor and epilepsy mainly with onset in adulthood. The clinical course is non‐progressive or slowly progressive, as epilepsy is commonly controlled with appropriate antiseizure medication and individuals have a normal life expectancy. However, the myoclonus severity increases with age and leads to some degree of disability in the elderly. Because the non‐coding repeat expansions responsible for FAME are not detected by routine genetic tests being used at this time, a clinical diagnosis accompanied by neurophysiological testing remains essential to guide the geneticist on the selection of the specific genetic technique. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies.

Author

Fernández-Anaya, Silvia, Villanueva, Vicente, Serratosa, José M., Rico-Villademoros, Fernando, Rojo, Rosa, and Sarasa, Pilar

Subjects
EPILEPSY, PARTIAL epilepsy, PEOPLE with epilepsy, SCIENTIFIC observation, RANDOM effects model, ACETATES
Abstract

To assess the effectiveness, overall tolerability of eslicarbazepine acetate (ESL) as an initial or early monotherapy treatment of adult patients with focal epilepsy under real-world practice conditions. We focused on real-world longitudinal studies that included or separately reported the results of at least one of the efficacy outcomes of interest. A DerSimonian-Laird random effects model was used with the presentation of the 95% confidence intervals of the estimate 5 studies met our selection criteria and were included in the quantitative synthesis. All studies were observational and uncontrolled studies, and all but one were retrospective studies. The pooled proportion of patients who were seizure-free for the entire study period was 64.6% (95% CI, 45.7 to 79.8) at month 6 and 56.6% (95% CI, 50.2 to 62.8) at month 12. Pooled retention rates were 95.0% (95% CI, 90.3 to 97.5) at 6 months and 83.6% (95% CI, 73.9 to 90.1) at 12 months. The pooled proportion of patients who reported at least one adverse event was 27.2% (95% CI, 21.7 to 33.6), and the pooled proportion of patients who discontinued ESL due to adverse events was 8.9% (95% CI 6.2 to 12.6). Our results suggest that initial or early monotherapy with ESL is effective and well-tolerated for the management of adult patients with focal epilepsy in clinical practice, with results that are at least similar to those reported in the pivotal randomized clinical trial of ESL monotherapy. No new safety signals with ESL have been identified in this systematic review. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. 4-Aminopyridine is a promising treatment option for patients with gain-of-function KCNA2 -encephalopathy

Author

Hedrich, Ulrike B. S., primary, Lauxmann, Stephan, additional, Wolff, Markus, additional, Synofzik, Matthis, additional, Bast, Thomas, additional, Binelli, Adrian, additional, Serratosa, José M., additional, Martínez-Ulloa, Pedro, additional, Allen, Nicholas M., additional, King, Mary D., additional, Gorman, Kathleen M., additional, Zeev, Bruria Ben, additional, Tzadok, Michal, additional, Wong-Kisiel, Lily, additional, Marjanovic, Dragan, additional, Rubboli, Guido, additional, Sisodiya, Sanjay M., additional, Lutz, Florian, additional, Ashraf, Harshad Pannikkaveettil, additional, Torge, Kirsten, additional, Yan, Pu, additional, Bosselmann, Christian, additional, Schwarz, Niklas, additional, Fudali, Monika, additional, and Lerche, Holger, additional

Published
2021
Full Text
View/download PDF

41. Clinical outcomes of eslicarbazepine acetate monotherapy for focal‐onset seizures: A multicenter audit

Author

Giráldez, Beatriz G., primary, Garamendi‐Ruiz, Iñigo, additional, Zurita, Jorge, additional, García, Alberto, additional, Querol, Rosa, additional, Campos, Dulce, additional, Cabeza‐Alvarez, Clara, additional, Serrano, Pedro, additional, López‐González, Francisco Javier, additional, Molins, Albert, additional, and Serratosa, José M., additional

Published
2019
Full Text
View/download PDF

47. Is Refractory Epilepsy Preventable?

Author

Arroyo, Santiago, Brodie, Martin J, Avanzini, Giuliano, Baumgartner, Christoph, Chiron, Catherine, Dulac, Olivier, French, Jacqueline A, and Serratosa, José M

Published
2002

50. De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy

Author

Syrbe, Steffen, Hedrich, Ulrike B S, Arslan, Mutluay, Serratosa, José M, Nothnagel, Michael, May, Patrick, Krause, Roland, Löffler, Heidrun, Detert, Katja, Dorn, Thomas, Vogt, Heinrich, Krämer, Günter, Riesch, Erik, Schöls, Ludger, Mullis, Primus E, Linnankivi, Tarja, Lehesjoki, Anna-Elina, Sterbova, Katalin, Craiu, Dana C, Hoffman-Zacharska, Dorota, Korff, Christian M, Weber, Yvonne G, Steinlin, Maja, Djémié, Tania, Gallati, Sabina, Bertsche, Astrid, Bernhard, Matthias K, Merkenschlager, Andreas, Kiess, Wieland, consortium, EuroEPINOMICS RES, Gonzalez, Michael, Züchner, Stephan, Palotie, Aarno, Suls, Arvid, Müller, Stephan, De Jonghe, Peter, Helbig, Ingo, Biskup, Saskia, Wolff, Markus, Maljevic, Snezana, Schüle, Rebecca, Sisodiya, Sanjay M, Weckhuysen, Sarah, Lerche, Holger, Lemke, Johannes R, Møller, Rikke S, Balling, Rudi, Barisic, Nina, Baulac, Stéphanie, Caglayan, Hande S, Depienne, Christel, Gormley, Padhraig, Guerrini, Renzo, Maher, Bridget, Hjalgrim, Helle, Jähn, Johanna, Klein, Karl Martin, Koeleman, Bobby P C, Komarek, Vladimir, LeGuern, Eric, Hernandez-Hernandez, Laura, Marini, Carla, Muhle, Hiltrud, Pal, Deb, Rosenow, Felix, Selmer, Kaja, Synofzik, Matthis, Stephani, Ulrich, Striano, Pasquale, Talvik, Tiina, von Spiczak, Sarah, Zara, Federico, and EuroEPINOMICS RES Consortium

Subjects
Adult, Male, Ataxia, genetics [Epilepsy], genetics [Kv1.2 Potassium Channel], Biology, medicine.disease_cause, Bioinformatics, Infantile, Epilepsy/genetics, Article, Spasms, Cohort Studies, Epilepsy, Young Adult, Spasms, Infantile/genetics, ddc:570, Amino Acid Sequence, Child, Child, Preschool, Female, Genetic Predisposition to Disease, Humans, Infant, Kv1.2 Potassium Channel, Pedigree, Spasms, Infantile, Mutation, Genetics, Intellectual disability, medicine, KCNA2 protein, human, Preschool, Loss function, Kv1.2 Potassium Channel/genetics, ddc:618, Genetic heterogeneity, Seizure types, genetics [Spasms, Infantile], medicine.disease, Myoclonic epilepsy, Human medicine, medicine.symptom
Abstract

Epileptic encephalopathies are a phenotypically and genetically heterogeneous group of severe epilepsies accompanied by intellectual disability and other neurodevelopmental features(1-6). Using next-generation sequencing, we identified four different de novo mutations in KCNA2, encoding the potassium channel K(V)1.2, in six isolated patients with epileptic encephalopathy (one mutation recurred three times independently). Four individuals presented with febrile and multiple afebrile, often focal seizure types, multifocal epileptiform discharges strongly activated by sleep, mild to moderate intellectual disability, delayed speech development and sometimes ataxia. Functional studies of the two mutations associated with this phenotype showed almost complete loss of function with a dominant-negative effect. Two further individuals presented with a different and more severe epileptic encephalopathy phenotype. They carried mutations inducing a drastic gain-of-function effect leading to permanently open channels. These results establish KCNA2 as a new gene involved in human neurodevelopmental disorders through two different mechanisms, predicting either hyperexcitability or electrical silencing of K(V)1.2-expressing neurons.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results